Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



Hepatitis C Drugmakers Hook Up to Develop Cocktail

Watch stocks you care about

The single, easiest way to keep track of all the stocks that matter...

Your own personalized stock watchlist!

It's a 100% FREE Motley Fool service...

Click Here Now

Merck (NYSE: MRK  ) may be late to the party, but at least it's found someone to go home with.

Hepatitis C drugmakers have been hooking up left and right in the hopes of developing an all-oral cocktail to treat the viral infection. Merck joins their ranks on Monday, announcing an agreement with Bristol-Myers Squibb (NYSE: BMY  ) to test its protease inhibitor MK-5172 with Bristol's NS5A inhibitor daclatasvir.

While this is the first hookup for Merck that I know of, Bristol has partnered out daclatasvir with anyone that would buy it a drink. There was a partnership with Phamasset, but Gilead Sciences (NASDAQ: GILD  ) dumped Bristol after buying Pharmasset. Bristol still has a partnership testing daclatasvir with Johnson & Johnson's (NYSE: JNJ  ) simeprevir and recently signed up Vertex Pharmaceuticals (NASDAQ: VRTX  ) as a partner to test daclatasvir with the biotech's hepatitis C drug, VX-135.

These really are hookups and not long-term marriages -- no polygamy here. There isn't any real commitment beyond initial trials to see if the drugs work well together. The partnership between Merck and Bristol covers a phase 2 trial that Merck will conduct. Vertex is running two phase 2 trials as part of its deal with Bristol. Neither press release mentioned who was paying for the trials.

If the drugs do work together, there's always an option of extending the partnership into phase 3 trials. Gilead didn't want to work with Bristol, but the driving force for the breakup had to do with the biotech having an NS5A inhibitor of its own. Most of the other hepatitis C drugmakers don't have that option. To create an effective cocktail,they'll need some help.

Bristol isn't the only one putting itself out there. Johnson & Johnson and Vertex both have other partnerships to test their compounds with other drugs, including with each other.

That's going to create some interesting dynamics down the line if a drug works with more than one partner. There could be a bidding war to get exclusivity or companies might choose to make their compounds available for use in multiple cocktails, which could be lucrative, but will also open up some conflicts of interest.

Interestingly, Merck has a NS5A inhibitor of its own called MK-8742. It isn't clear to me whether the partnership with Bristol is a backup plan or if the development of MK-8742 is dead. lists a trial testing MK8742 with MK-5172 and ribavirin as still recruiting.

Being late to the party developing an all-oral cocktail, it's understandable that Merck might want to keep all of its options open.

Can Merck beat the patent cliff?
This titan of the pharmaceutical industry stumbled into 2013 and continues to battle patent expirations and pipeline problems. Is Merck still a solid dividend play, or should investors be looking elsewhere? In a new premium research report on Merck, The Fool tackles all of the company's moving parts, its major market opportunities, and reasons to both buy and sell. To find out more click here to claim your copy today.

Read/Post Comments (0) | Recommend This Article (1)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2377709, ~/Articles/ArticleHandler.aspx, 10/1/2016 3:06:28 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 17 hours ago Sponsored by:
DOW 18,308.15 164.70 0.91%
S&P 500 2,168.27 17.14 0.80%
NASD 5,312.00 42.85 0.81%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

9/30/2016 4:05 PM
BMY $53.92 Up +0.05 +0.09%
Bristol-Myers Squi… CAPS Rating: ****
MRK $62.41 Up +0.50 +0.81%
Merck and Co. CAPS Rating: ****
GILD $79.12 Up +1.26 +1.62%
Gilead Sciences CAPS Rating: *****
JNJ $118.13 Up +0.86 +0.73%
Johnson and Johnso… CAPS Rating: *****
VRTX $87.21 Up +2.21 +2.60%
Vertex Pharmaceuti… CAPS Rating: ****